Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wenyanghuazhuo formula is a Traditional Chinese Medicine (TCM) herbal decoction developed by the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine. It is specifically designed to treat chronic endometritis (CE) in patients experiencing recurrent implantation failure (RIF) during assisted reproductive technology (ART) cycles. The formula is based on the TCM principle of warming yang and transforming turbidity to improve the intrauterine environment. Mechanistically, it is thought to enhance endometrial receptivity by modulating the local immune response, reducing the infiltration of CD138+ plasma cells, and downregulating pro-inflammatory cytokines such as TNF-α and IL-6. By alleviating chronic inflammation and improving uterine blood flow, the formula aims to increase the success rates of embryo implantation and clinical pregnancy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on wenyanghuazhuo formula.